XFOR

0.3602

8.83% -0.0349

Dopo l'orario di chiusura: .36 -0.0002 -0.06%

X 4 Pharmaceuticals Inc (XFOR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.3951

Aprire:

$0.4075

Volume 24 ore:

1.27M

Relative Volume:

0.32

Capitalizzazione di mercato:

$66.91M

Reddito:

Utile/perdita netta:

$-16.76M

Rapporto P/E:

-4.5025

EPS:

-0.08

Flusso di cassa netto:

$-132.97M

1 W Prestazione:

-20.63%

1M Prestazione:

-39.98%

6M Prestazione:

-45.37%

1 anno Prestazione:

-64.34%

Intervallo 1D:

$0.36

$0.4182

Intervallo di 1 settimana:

$0.36

$0.4599

Portata 52W:

$0.2612

$1.60

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Nome

X 4 Pharmaceuticals Inc

Settore

Healthcare (1189)

Industria

Biotechnology (682)

Telefono

857-529-8300

Indirizzo

61 NORTH BEACON STREET, BOSTON, MA

Dipendente

143

Cinguettio

@x4pharma

Prossima data di guadagno

2024-11-13

Ultimi documenti SEC

XFOR's Discussions on Twitter

Confronta XFOR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
XFOR X 4 Pharmaceuticals Inc	0.3602	66.91M	0	-16.76M	-132.97M	-0.08
VRTX Vertex Pharmaceuticals Inc	483.31	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	684.87	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	622.61	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	243.53	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	111.56	27.34B	3.30B	-501.07M	1.03B	-2.1146

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-12	Downgrade	B. Riley Securities	Buy → Neutral
2023-08-30	Ripresa	B. Riley Securities	Buy
2022-12-22	Iniziato	Cantor Fitzgerald	Overweight
2022-12-12	Iniziato	Piper Sandler	Overweight
2019-12-23	Iniziato	Oppenheimer	Outperform
2019-12-18	Iniziato	ROTH Capital	Buy
2019-12-09	Aggiornamento	Citigroup	Neutral → Buy
2019-12-05	Iniziato	B. Riley FBR	Buy
2019-06-07	Iniziato	Stifel	Buy
2019-06-05	Iniziato	Cowen	Outperform

Mostra tutto

X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie

02:18 AM

Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace

02:18 AM

07:51 AM

How pharma CEO pay shifted for these 4 companies last year - PharmaVoice

07:51 AM

03:25 AM

Atria Wealth Solutions Inc. Buys New Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World

03:25 AM

Feb 28, 2025

President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4) - Quantisnow

Feb 28, 2025

ANI Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 28, 2025

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Yahoo Finance

Feb 28, 2025

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease - Quantisnow

Feb 28, 2025

Feb 27, 2025

Earnings call transcript: Xenon Pharmaceuticals Q4 2024 sees slight EPS beat - Investing.com

Feb 27, 2025

Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World

Feb 27, 2025

Feb 26, 2025

President and CEO Polymeropoulos Mihael Hristos bought $47,650 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,341,730 units (SEC Form 4) - Quantisnow

Feb 26, 2025

Popular lemonade recalled by FDA for cancer-linked chemical - New York Post

Feb 26, 2025

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - Business Wire

Feb 26, 2025

Feb 25, 2025

President and CEO Polymeropoulos Mihael Hristos bought $44,640 worth of shares (10,000 units at $4.46), increasing direct ownership by 0.43% to 2,331,730 units (SEC Form 4) - Quantisnow

Feb 25, 2025

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire

Feb 25, 2025

Feb 24, 2025

SVP, CFO & Treasurer Moran Kevin Patrick bought $8,779 worth of shares (2,000 units at $4.39), increasing direct ownership by 0.57% to 355,763 units (SEC Form 4) - Quantisnow

Feb 24, 2025

3 Pharmaceutical Stocks With Blockbuster Drug Potential - TradingView

Feb 24, 2025

Licensing For Innovation: A Decade Of Pharma Product Deals - Insights

Feb 24, 2025

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - Business Wire

Feb 24, 2025

DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD) - PR Newswire

Feb 24, 2025

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - Morningstar

Feb 24, 2025

Feb 20, 2025

SVP, CFO & Treasurer Moran Kevin Patrick was granted 125,000 shares, increasing direct ownership by 55% to 353,763 units (SEC Form 4) - Quantisnow

Feb 20, 2025

Feb 19, 2025

X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries -February 19, 2025 at 10:56 am EST - Marketscreener.com

Feb 19, 2025

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - Marketscreener.com

Feb 19, 2025

X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI®? in WHIM Syndrome in Select Middle East Countries - Marketscreener.com

Feb 19, 2025

Feb 16, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 22.6% in January - MarketBeat

Feb 16, 2025

Feb 15, 2025

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance

Feb 15, 2025

Feb 14, 2025

X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock By Investing.com - Investing.com South Africa

Feb 14, 2025

X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock - Investing.com India

Feb 14, 2025

Feb 13, 2025

HC Wainwright Cuts Earnings Estimates for X4 Pharmaceuticals - MarketBeat

Feb 13, 2025

Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech

Feb 13, 2025

Feb 12, 2025

SG Americas Securities LLC Increases Stock Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World

Feb 12, 2025

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire

Feb 12, 2025

Feb 11, 2025

Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights

Feb 11, 2025

FY2027 EPS Forecast for X4 Pharmaceuticals Cut by Analyst - Defense World

Feb 11, 2025

FY2028 Earnings Estimate for XFOR Issued By HC Wainwright - Defense World

Feb 11, 2025

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Business Wire

Feb 11, 2025

Feb 10, 2025